Multiple Sclerosis Banner

Featured Article

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy

The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.

Latest

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Presence of CHI3L1 and NFL in CSF Predicts Risk for Demyelinating Syndromes

Investigators assess the diagnostic value of 2 CSF biomarkers to distinguish pediatric acquired demyelinating syndromes from non-acquired demyelinating syndromes.

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

The NDA resubmission is in response to the FDA's Complete Response Letter issued in 2011 which requested an improved understanding of the safety risks and overall benefit-risk profile.

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

Organic Solvents Plus Genetics May Increase Risk of Multiple Sclerosis

The combination of genetics and exposure to organic solvents in paints and varnishes increases the risk of multiple sclerosis.

Dynamics of Brain Volume Loss Vary With MS Progression

Dynamics of Brain Volume Loss Vary With MS Progression

Brain volume loss has nonlinear dynamics and limited reproducibility as a marker of therapeutic response in multiple sclerosis.

Reduced Disability Progression, Adverse Events Top Considerations When Selecting Multiple Sclerosis Therapy

Reduced Disability Progression, Adverse Events Top Considerations When Selecting Multiple Sclerosis Therapy

A majority of the respondents in both groups identified reduced disability progression as a priority.

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

Gait in Multiple Sclerosis Improved With Dalfampridine Plus Physical Therapy

A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Medical Cannabis Shows Promise in Treating Symptoms of Multiple Sclerosis

Differing formulations and ratios of the subjects' medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Multiple Sclerosis Pain Common Disruptive Factor in Everyday Activities

Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

Dimethyl Fumarate Not Associated With Greater Pain vs Other DMTs in Relapsing-Remitting MS

Investigators assessed the effect of disease-modifying treatments on pain in patients with relapsing-remitting multiple sclerosis.

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

Skin Tone, Race May Be Associated With Multiple Sclerosis Diagnosis

The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.

Sign Up for Free e-newsletters



CME Focus